BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,132 filers reported holding BAXTER INTL INC in Q2 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $543,328 | -6.7% | 16,243 | +19.2% | 0.04% | -9.5% |
Q1 2024 | $582,431 | +26.6% | 13,627 | +14.5% | 0.04% | +13.5% |
Q4 2023 | $460,066 | -10.2% | 11,900 | -12.3% | 0.04% | -22.9% |
Q3 2023 | $512,263 | +111.0% | 13,573 | +154.7% | 0.05% | +100.0% |
Q2 2023 | $242,753 | -3.7% | 5,328 | -14.3% | 0.02% | -11.1% |
Q1 2023 | $252,103 | -71.8% | 6,216 | -64.5% | 0.03% | -74.8% |
Q4 2022 | $893,200 | -5.3% | 17,524 | +0.1% | 0.11% | -11.6% |
Q3 2022 | $943,000 | -15.7% | 17,509 | +0.6% | 0.12% | -15.4% |
Q2 2022 | $1,118,000 | -19.7% | 17,410 | -3.0% | 0.14% | +3.6% |
Q1 2022 | $1,392,000 | -9.1% | 17,946 | +0.5% | 0.14% | -14.3% |
Q4 2021 | $1,532,000 | +3.0% | 17,851 | -3.4% | 0.16% | -11.5% |
Q3 2021 | $1,487,000 | +2.1% | 18,486 | +2.1% | 0.18% | -5.7% |
Q2 2021 | $1,457,000 | -11.4% | 18,097 | -7.2% | 0.19% | -23.1% |
Q1 2021 | $1,645,000 | -2.9% | 19,500 | -7.7% | 0.25% | -14.6% |
Q4 2020 | $1,695,000 | -17.2% | 21,120 | -17.0% | 0.29% | -25.6% |
Q3 2020 | $2,046,000 | -27.2% | 25,440 | -22.1% | 0.40% | -38.3% |
Q2 2020 | $2,811,000 | +15.2% | 32,652 | +8.6% | 0.64% | -5.9% |
Q1 2020 | $2,441,000 | – | 30,066 | – | 0.68% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |